Table 4.
p-value | |
---|---|
Diagnosis | |
Cholangiocarcinoma vs. HCC | 0.832 |
Neuroendocrine liver metastasis vs. HCC | 0.863 |
Age (yr) | |
≥65 vs. <65 | 0.511 |
Sex | 0.888 |
Male vs. female | |
Child–Pugh classification | 0.358 |
B vs. A | |
Dose fractionation | |
30–35 Gy vs. <30 Gy in 5 fx | 0.915 |
40–45 Gy vs. <30 Gy in 5 fx | 0.819 |
50+ Gy vs. <30 Gy in 5 fx | 0.781 |
PTV volume (mL) | |
50–100 vs. <50 | 0.866 |
100–250 vs. <50 | 0.736 |
250–500 vs. <50 | 0.607 |
500+ vs. <50 | 0.429 |
Treatment response | |
Responders (SD+PR+CR) vs. non-responders (PD) | 0.001 |
HCC, hepatocellular carcinoma; PTV, planning target volume; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.